00000nam 2200000za 4500 9.853982 CaOODSP 20221107154946 cr ||||||||||| 181029s2018 oncd|||#o f000 0 eng d 9780660258522 CaOODSP eng n-cn--- HP40-212/2018E-PDF Updated recommendations on the use of herpes zoster vaccines [electronic resource]. At head of title: Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) Ottawa : Public Health Agency of Canada, 2018. 177 p. : col. charts. Issued also in French under title: Recommandations à jour sur l’utilisation des vaccins contre le zona. Includes bibliographic references: p. 63-72. "The need for this updated National Advisory Committee on Immunization (NACI) Advisory Committee Statement on the Use of Herpes Zoster (HZ) Vaccines was triggered by evidence on a newly authorized Recombinant subunit Zoster Vaccine (RZV) vaccine, Shingrix®, indicated for the prevention of HZ in individuals 50 years of age and older. The primary objective of this statement is to review current evidence and develop guidance on the use of Shingrix®, as well as to provide guidance on whether the previously authorized Live Zoster Vaccine (LZV), Zostavax®II, and/or the recently authorized RZV should be offered to Canadians ≥50 years of age and older"--Introd., p. 6. gccst Immunization gccst Infectious diseases Public Health Agency of Canada. Infectious Disease Prevention and Control Branch. Recommandations à jour sur l’utilisation des vaccins contre le zona (CaOODSP)9.853984 PDF 2.32 MB https://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-212-2018-eng.pdf Pub.: 170531